Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at Wall Street Zen
Wall Street Zen downgraded Arbutus Biopharma (NASDAQ:ABUS) from a "buy" to a "hold" rating, though Weiss Ratings simultaneously upgraded it from "sell" to "hold." The biopharmaceutical company holds a consensus "Moderate Buy" rating and a $5.00 price target. Despite missing quarterly EPS estimates by $0.01 with a loss of $0.03 per share, Arbutus Biopharma exceeded revenue expectations at $1.01 million.
Form 8K Arbutus Biopharma Corp For: 12 August By Investing.com
This article reports on an 8K filing by Arbutus Biopharma Corp (ABUS) for August 12. The brief announcement from Investing.com indicates this is a financial market update. No specific details about the content of the 8K filing are provided within the article.
Arbutus Biopharma (ABUS) Stock Profit Surge Leaves Durability Questions Open
Arbutus Biopharma (ABUS) recently became profitable, with a significant surge in revenue and net income in Q2 2026, leading to a low trailing P/E of 5.6x. Despite this financial improvement, the stock has seen a muted market reaction and recent declines, suggesting investors are uncertain about the sustainability of its profitability and remain focused on its early-stage pipeline. The article highlights both the bullish case for profitability and the bearish concerns regarding clinical risk and share price weakness.
Morgan Stanley (ABUS) units report near-9% Arbutus Biopharma stake in 13G/A filing
Morgan Stanley and Morgan Stanley Investment Management Inc. have disclosed significant beneficial ownership in Arbutus Biopharma Corp (ABUS) common shares through a Schedule 13G/A filing. As of June 30, 2026, Morgan Stanley reporting units beneficially own 8.8% of Arbutus Biopharma's common shares, while Morgan Stanley Investment Management Inc. holds an 8.7% stake, with both entities exercising shared voting and dispositive power. The filing specifies that it covers only certain Morgan Stanley units and may not include all holdings across the firm.
Arbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS
Arbutus Biopharma (NASDAQ:ABUS) reported a quarterly loss of $0.03 per share, missing analyst expectations by $0.01. Despite the earnings miss, the company's revenue of $1.01 million surpassed the consensus estimate of $0.70 million. Following the announcement, ABUS shares declined by 3.0% to $4.53, while institutional ownership of the company increased, with hedge funds and asset managers boosting their positions.
Arbutus Biopharma Announces Q2 2026 Financial Results Highlighting Genevant License Revenue Impact
Arbutus Biopharma Corporation reported its Q2 2026 financial results, showcasing a significant net income of $164,552 thousand for the six months ending June 30, 2026, primarily due to $179,373 thousand in license revenue from Genevant. This marks a substantial improvement from a net loss in the prior year, with total assets and stockholders' equity also seeing considerable increases. Despite a Q2 2026 net loss of $5,143 thousand, the company's overall financial health was bolstered by the Genevant revenue and reduced operating expenses.
Arbutus Biopharma Corp 2026: Revenue $1.01M, EPS ($0.03) — 10-Q Summary
Arbutus Biopharma Corp reported its Q2 2026 results with revenue of $1.01M and a net loss of ($5.14M), a significant decrease from the prior year's $10.74M revenue and $2.52M net income. The diluted EPS was ($0.03) compared to $0.01 a year earlier. Key business highlights include a $178.4M settlement with Moderna, FDA Fast Track designation for Imdusiran, ongoing cost reductions, and continued enforcement of LNP/IP rights.
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving Average - Should You Sell?
Arbutus Biopharma (NASDAQ:ABUS) shares have moved above their 200-day moving average, reaching $4.67 before closing at $4.59. The company's financial performance includes a quarterly EPS of $0.87 and $179.13 million in revenue, while institutional investors collectively hold 43.79% of its shares. Analyst sentiment is divided, with one Buy and one Sell rating, leading to a consensus Hold rating and a $5.00 price target.
Arbutus Biopharma Corp (ABUS) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Arbutus Biopharma Corp (ABUS), highlighting its current earnings forecast score of 9.00 and an average price target of $5.00 from 2 analysts, who recommend a "Strong Buy". It also details expected revenue for the next quarter and past EPS performance.
Arbutus Biopharma Corp (ABUS) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Arbutus Biopharma Corp (ABUS), detailing its current risk score of 5.75 and ranking within the Biotechnology & Medical Research industry. It highlights the company's beta value of 0.63, indicating lower volatility compared to the S&P 500 index. The assessment further breaks down various risk metrics including VaR, maximum drawdown, volatility, and Sharpe Ratios over different periods, offering insights into the stock's performance and risk profile.
Arbutus Biopharma Corp (ABUS) Institutional Confidence
The institutional confidence score for Arbutus Biopharma Corp (ABUS) is 5.00, placing it 132nd within the Biotechnology & Medical Research industry. Institutional shareholding increased by 3.63% quarter-over-quarter, reaching 65.56%. Roivant Sciences Ltd. is the largest institutional shareholder with 38.85M shares, while Morgan Stanley Investment Management Inc. (US) significantly increased its holdings by 9.87%.
Arbutus Biopharma Corp (ABUS) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Arbutus Biopharma Corp (ABUS), noting its current valuation score of 8.62, which ranks it 106 out of 384 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at 5.17, significantly above its recent low but below its high. Other key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
ABUS|Arbutus Biopharma Corp|Price:4.280|Chg%:-0.130
TradingKey provides a comprehensive stock analysis of Arbutus Biopharma Corp (ABUS), highlighting its strong fundamentals and high growth potential despite a weak stock market performance. The company's valuation is considered fair, ranking 35th in its industry, with high institutional ownership. Analysts have given it a "Buy" rating with a target price of $5.25.
Arbutus Biopharma Corp (ABUS) Financial Health: Profitability & Balance Sheet Analysis
Arbutus Biopharma Corp (ABUS) has a strong financial health score of 8.63, ranking 37 out of 386 in the Biotechnology & Medical Research industry, indicating robust financial status and high operating efficiency. The company reported a significant year-over-year revenue increase of 10054.54% to 179.13M, and a net profit increase of 791.90%. Several key financial metrics like cash and cash equivalents, total assets, and free cash flow were not disclosed, and segments like Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns also lacked explicit data.
ADAR1 Capital Management LLC Has $14.10 Million Position in Arbutus Biopharma Corporation $ABUS
ADAR1 Capital Management LLC significantly reduced its stake in Arbutus Biopharma Corporation by 42.1% in the first quarter, yet still holds 3.13 million shares valued at $14.10 million. Despite ADAR1's reduction, other institutional investors, such as Goldman Sachs, increased their positions, with institutional investors and hedge funds collectively owning 43.79% of the stock. Analyst sentiment for Arbutus Biopharma is mixed, resulting in a consensus "Hold" rating and a target price of $5.00, while the company reported $0.87 quarterly EPS and $179.13 million in revenue.
Arbutus Biopharma Corp (ABUS) Balance Sheet
This article provides the quarterly and annual balance sheets for Arbutus Biopharma Corp (ABUS), allowing users to evaluate its financial health, analyze fundamentals, and calculate key financial ratios. It includes detailed data on assets, liabilities, and shareholders' equity, covering a historical period. The content also features an FAQ section addressing important balance sheet metrics and specific figures for ABUS's cash, assets, liabilities, and shareholders' equity for the most recent quarter.
Arbutus Biopharma Corp (ABUS) Cash Flow
The article provides a detailed quarterly and annual cash flow statement for Arbutus Biopharma Corp (ABUS), enabling evaluation of its financial soundness. It highlights current operating cash flow at -39.64M in fiscal 2025, which increased by 38.88% year-over-year, and details changes in investing and financing cash flows, including a -5.72M use in financing activities in the latest quarter.
ABUS|Arbutus Biopharma Corp|Price:4.380|Chg%:-0.090
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focusing on infectious diseases, specifically chronic hepatitis B (cHBV). Their pipeline includes imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor. The article also provides corporate information, executive details, and institutional shareholding data for ABUS.
Arbutus Biopharma Corp (ABUS) Income Statement
This article provides the quarterly and annual income statements for Arbutus Biopharma Corp (ABUS), offering detailed financial data such as total revenue, operating expenses, net income, and earnings per share. It also includes an FAQ section explaining how to read the income statement, distinguishing between quarterly and annual data, defining "YOY," and highlighting key metrics for analyzing ABUS stock performance.
Arbutus Biopharma Corp (ABUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Arbutus Biopharma Corp (ABUS), focusing on its support and resistance levels, key indicators, and moving averages. As of July 24, 2026, the stock's price momentum score is 4.10, and it is trading between a resistance level of 5.09 and a support level of 3.96. While various technical indicators show a "Neutral" overall signal, moving averages indicate a mix of buy and sell signals.
ABUS|Arbutus Biopharma Corp|Price:4.385|Chg%:-0.085
This article provides a detailed financial overview of Arbutus Biopharma Corp (ABUS), including its latest earnings report, key financial indicators like EPS, revenue, net profit, and margins across quarterly and annual periods. It presents comprehensive income statement, balance sheet, and cash flow statement data, along with answers to frequently asked questions about the company's financials for FY2025.
Arbutus Biopharma Corp (ABUS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Arbutus Biopharma Corp (ABUS), listing its major shareholders and their proportions, including Roivant Sciences Ltd. and Morgan Stanley Investment Management Inc. It also categorizes shareholders by type and provides a historical overview of institutional holdings, showing changes in the number of institutions and shares held over several quarters. Additionally, it lists ETFs with holdings in ABUS.
Arbutus Biopharma Corp (ABUS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Arbutus Biopharma Corp (ABUS) has an earnings forecast score of 8.67, ranking 72nd in the Biotechnology & Medical Research industry, with an average price target of $5.00 from three analysts. Analysts generally recommend a "Buy" for ABUS stock. The company's expected revenue for the next quarter is $450.00K, and the expected EPS for the next quarter is -$0.03.
ABUS|Arbutus Biopharma Corp|Price:4.460|Chg%:+0.130
Arbutus Biopharma Corp (ABUS) shows healthy fundamentals and high growth potential, with its valuation considered fair within the Biotechnology & Medical Research industry. Institutional ownership is notably high, and analysts currently rate the stock as a "Buy" with a target price reflecting a decent upside. The company is developing therapies for chronic hepatitis B and its stock price is currently in a sideways trend.
Arbutus Plans $230M Buyback as Patent Fight Expands
Arbutus Biopharma Corp. plans to return up to $230 million to shareholders, partially funded by a $178 million settlement from Moderna related to lipid nanoparticle patent infringement. This shareholder return is expected to begin in Q3 2026, pending board approval and receipt of a dividend from Genevant Sciences. Additionally, Arbutus and Genevant have expanded their patent litigation against Pfizer and BioNTech, filing new lawsuits in Canada and Europe over alleged infringement of mRNA vaccine technology.
Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNT Over Patent Dispute
Arbutus Biopharma (ABUS) and Genevant Sciences have filed three international lawsuits against Pfizer and BioNTech, alleging patent infringement related to their COVID-19 vaccine's lipid nanoparticle technology. This action follows a similar U.S. dispute and a $178 million settlement with Moderna. Arbutus Biopharma, a clinical-stage biopharmaceutical company with a perfect financial strength rating (10/10) but low profitability and growth scores, currently has a P/E ratio of 5.5, suggesting it may be undervalued.
Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNTech Over Patent Dispute
Arbutus Biopharma (ABUS) and Genevant Sciences have initiated three international lawsuits against Pfizer and BioNTech, alleging patent infringements related to their COVID-19 vaccine's lipid nanoparticle technology. This action follows a prior U.S. dispute and a $178 million settlement with Moderna. Despite strong financial stability (10/10), Arbutus has low profitability and growth scores, and its P/E ratio of 5.5 suggests it may be undervalued.
Arbutus (ABUS) Secures $178 Million Settlement with Moderna
Arbutus Biopharma Corp (ABUS) has secured a $178 million settlement with Moderna to resolve patent infringement disputes related to Moderna’s COVID-19 vaccines. This payment will bolster Arbutus's cash reserves and allow it to focus on its core business of developing therapeutics for infectious diseases. Despite strong financial strength, Arbutus's low profitability and growth ranks, coupled with a "Possible Value Trap" classification, suggest investors should proceed with caution.
Arbutus Biopharma Files International Patent Lawsuits Against Pfizer and BioNTech, Announces Moderna Settlement Payment and Plans for Capital Return
Arbutus Biopharma and its licensee Genevant have filed three international lawsuits against Pfizer and BioNTech for patent infringement related to their lipid nanoparticle technology, seeking monetary damages and injunctions. This follows Arbutus receiving approximately $178 million from Moderna to settle a similar patent dispute. Arbutus also expects a dividend from Genevant in Q3 2026 and plans to return up to $230 million in capital to shareholders through share repurchases, contingent on board approval and the dividend receipt.
Arbutus Biopharma (Nasdaq: ABUS) receives $178M from Moderna, eyes $230M buyback
Arbutus Biopharma received approximately $178 million from a settlement with Moderna regarding mRNA patent disputes and may receive up to an additional $1.3 billion. The company also announced plans to return up to $230 million to shareholders through common share repurchases, contingent on board approval and a dividend from Genevant. Additionally, Arbutus and Genevant have initiated three international patent infringement lawsuits against Pfizer/BioNTech over lipid nanoparticle technology.
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Arbutus Biopharma, and its licensee Genevant, have initiated three international lawsuits against Pfizer and BioNTech for patent infringement related to their innovative LNP technology used in COVID-19 vaccines. Concurrently, Arbutus announced the receipt of approximately $178 million from Moderna as part of a previous settlement agreement and plans to return up to $230 million in capital to shareholders, commencing in Q3 2026. The company also anticipates receiving a dividend from Genevant's parent in Q3 2026.
Arbutus Biopharma stock hits 52-week high at 5.34 USD By Investing.com
Arbutus Biopharma's stock reached a 52-week high of $5.34, reflecting strong investor confidence with a 56% return over the past year and a market capitalization of $1.05 billion. The company holds an "EXCELLENT" financial health score and its drug imdusiran recently received Fast Track designation from the FDA for chronic hepatitis B treatment, potentially accelerating its market entry.
Arbutus Biopharma stock hits 52-week high at 5.34 USD By Investing.com
Arbutus Biopharma's stock has reached a new 52-week high of $5.34, demonstrating robust performance with a 56% return over the past year and an "EXCELLENT" financial health score. This surge follows the FDA granting Fast Track designation to its drug imdusiran for chronic hepatitis B, potentially accelerating its market entry. The company's market capitalization stands at $1.05 billion, with the stock currently trading near its fair value according to InvestingPro analysis.
Arbutus Biopharma (ABUS) Joins Russell Defensive Indexes And Exits Value Benchmarks
Arbutus Biopharma (ABUS) has been added to the Russell 2000 Growth Defensive and Russell 2000 Defensive Indexes, while simultaneously being removed from several value-oriented Russell indexes. This reclassification may influence the types of index-linked funds and mandates that hold ABUS, shifting attention from value to growth and defensive investors. Despite strong past stock performance, analysts forecast a significant decline in earnings for Arbutus Biopharma over the next three years, indicating that index status does not mitigate fundamental earnings risks.
Arbutus Biopharma stock hits 52-week high at 5.34 USD
Arbutus Biopharma's stock has reached a new 52-week high of $5.34, reflecting strong investor confidence and a 56% return over the past year. The company, with a market capitalization of $1.05 billion, has an "EXCELLENT" financial health score and an impressive gross profit margin of 89%. Additionally, the FDA granted Fast Track designation to its drug imdusiran for chronic hepatitis B, potentially accelerating its market entry.
Arbutus Biopharma (NASDAQ:ABUS) Trading Down 6.2% - Here's Why
Arbutus Biopharma (NASDAQ:ABUS) shares fell 6.2% on Friday, trading as low as $4.84 with significantly lower than average volume. Despite strong recent quarterly results including $0.87 EPS and $179.13 million in revenue, analysts predict a full-year EPS of -$0.16. Analyst sentiment is mixed, with a "Hold" consensus rating and an average price target of $5.00, influenced by a recent upgrade to "Buy" from Wall Street Zen and a reiterated "Sell" from Weiss Ratings.
ABUS - Arbutus Biopharma Corp Options
This article provides a detailed overview of Arbutus Biopharma Corp (ABUS) stock options and key financial metrics. It includes recent stock performance, company financials like market cap, income, sales, and various ratios, along with insider and institutional ownership data. The information presented aims to give a comprehensive snapshot of the company's financial health and market position.
Arbutus Biopharma Corp (ABUS) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Arbutus Biopharma Corp (ABUS), noting its current valuation score of 8.58, which ranks it 115 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of 5.38, which is slightly below its recent high, but significantly above its recent low. The analysis also mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Arbutus Biopharma Corp (ABUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
The article provides a technical analysis of Arbutus Biopharma Corp (ABUS), focusing on its support and resistance levels, various technical indicators, and moving averages. It highlights that ABUS currently has a price momentum score of 8.98 and is trading between a resistance level of 4.87 and a support level of 4.14. Based on the analysis, the overall signal for ABUS is a "Buy" due to strong moving average performance.
Arbutus Biopharma Corp (ABUS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Arbutus Biopharma Corp (ABUS) has an earnings forecast score of 8.67, ranking well within the Biotechnology & Medical Research industry. Analysts provide an average price target of $5.00 with a Buy rating. The company's expected revenue for the next quarter is $450.00K, and the EPS for the next quarter is projected at $-0.03.
Arbutus Biopharma Corp (ABUS) Institutional Confidence
The article details the institutional confidence score for Arbutus Biopharma Corp (ABUS), which currently stands at 5.00, ranking it 133rd out of 388 in its industry. Institutional shareholding has increased to 65.56%, a 3.63% quarter-over-quarter rise. The largest institutional holder is ETHSX, though its holdings decreased by 14.29%.
Arbutus Biopharma Corp (ABUS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Arbutus Biopharma Corp (ABUS), identifying its major shareholders, their proportional holdings, and the types of shareholders. It also provides institutional shareholding data over various quarters and lists related ETFs that hold ABUS shares.
Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results
Arbutus Biopharma Corporation (ABUS) announced significant Q1 2026 results, reporting $179.1 million in revenue, a substantial increase from $1.8 million a year prior, largely due to a litigation settlement with Moderna. The company swung from a $24.5 million loss to a net income of $169.7 million, with reduced R&D expenses and a solid financial position of $95.2 million in cash and investments. Additionally, the U.S. FDA granted Fast Track designation to Arbutus's imdusiran program, potentially accelerating its development and review.
Arbutus Biopharma (Nasdaq:ABUS) - Stock Analysis
Arbutus Biopharma (ABUS) is a clinical-stage biopharmaceutical company focused on developing therapies for infectious diseases, particularly chronic Hepatitis B virus (HBV). The company became profitable this year, exceeding analyst expectations for its first quarter 2026 earnings, yet revenue and earnings growth are paradoxically forecast to decline in the future presenting a major risk. ABUS is advancing its lead candidate Imdusiran, an RNAi therapeutic for HBV that has received U.S. FDA Fast Track designation, and is involved in significant patent litigation regarding its LNP technology used in mRNA vaccines, which could lead to substantial financial outcomes.
Arbutus Biopharma (ABUS) director awarded fully vested options on 78,800 shares
Arbutus Biopharma director Roger Sawhney was granted fully vested stock options for 78,800 common shares at an exercise price of $4.24 per share, matching the closing price on the grant date of June 8, 2026. This equity compensation award is immediately exercisable and expires on June 8, 2036. The transaction is a grant, not an open-market purchase or sale of shares.
[Form 4] Arbutus Biopharma Corp Insider Trading Activity
Arbutus Biopharma director Robert A. Beardsley was granted 78,800 fully vested stock options with an exercise price of $4.24 per share, expiring on June 8, 2036. This transaction is categorized as a compensation-related award, not an open-market purchase or sale. The options are immediately exercisable.
ABUS - Arbutus Biopharma Corp Stock Price and Quote
This page provides a comprehensive overview of Arbutus Biopharma Corp (ABUS) stock, including its latest trading data, financial metrics, analyst ratings, and recent news headlines. Key financial figures like market cap, income, sales, and employee count are listed, alongside performance indicators and insider/institutional ownership details. The article also includes a detailed history of analyst recommendations and a timeline of corporate news and financial results.
Shareholders at Arbutus Biopharma (NASDAQ: ABUS) approve 2026 share plan and auditor
Arbutus Biopharma Corporation's shareholders approved the 2026 Omnibus Share and Incentive Plan, authorizing 16,300,000 common shares for equity-based compensation. They also re-elected all director nominees, approved executive compensation on a non-binding advisory basis, and ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026. The decisions were made at the company's 2026 Annual General and Special Meeting of Shareholders.
Two Seas (NASDAQ: ABUS) reports 18.56M Arbutus shares; 9.4% stake
Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi have reported a beneficial ownership of 18,557,543 common shares, representing a 9.4% stake in Arbutus Biopharma Corporation (NASDAQ: ABUS). This stake is held through two funds: Two Seas Global (Master) Fund LP and Two Seas LNP Opportunities (Master) Fund LP. The reporting persons have sole voting and dispositive power over these shares, calculated based on 196,947,757 common shares outstanding as of March 31, 2026.
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation reported strong first-quarter 2026 financial results, including $179.1 million in total revenue, primarily from a litigation settlement with Moderna. The company also announced that its investigational drug, imdusiran, received Fast Track designation from the FDA for chronic hepatitis B, indicating its potential to address an unmet medical need and accelerate development. Arbutus ended the quarter with a strong financial position, holding $95.2 million in cash, cash equivalents, and marketable securities.
